Formulary Watch |

Patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma were more likely to have a COVID-19 breakthrough infection.

Smaller PBMs are rated higher by health plans in terms of satisfaction because of their ability to offer more customized solutions.

The safety labeling for the beta interferons that are used to treat multiple sclerosis have been updated to include warnings about injection site reactions.

Paxlovid, an at-home treatment for COVID-19, reduces illness severity, hospitalizations, and deaths among adults by 89%.

CVS Caremark has removed 10 branded products from its formulary and added about 30 additional products.

The studies conducted to support Verzenio’s most recent approval for the treatment of high-risk early breast cancer provided additional safety data.

The antidepressant fluvoxamine reduced the need for hospitalization in high-risk patients, according to a new study.

UK regulatory authorities approved molnupiravir to treat patients with mild-to-moderate COVID-19.

This Tufts study has found that plans that restrict orphan drugs do so by narrowing the patient population who can receive them.

Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.

The agency needs more time to review new information on the analytical method used.

But groups such as Doctors Without Borders say the agreement with the Medicines Patent Pool excludes key manufacturing countries.

EmsanaRx, the new PBM, aims to provide large employers with flexibility and transparency on drug spending.

Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.

Specialty drug prices are rising as these therapeutics replace lower-cost therapies.

Seglentis’ co-crystal formulation targets four complementary pain relief mechanisms.

The label now includes new data from the trial that supported Cyltezo’s application for interchangeability with Humira.